Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19
Authors
Keywords
COVID-19, Tumour necrosis factor (TNF), Cytokines, International standards, Clinical trials, Therapy, SARS-COV-2
Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 140, Issue -, Pages 111785
Publisher
Elsevier BV
Online
2021-05-29
DOI
10.1016/j.biopha.2021.111785
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Covid-19: Arthritis drugs improve survival in intensive care patients, shows study
- (2021) Jacqui Wise BMJ-British Medical Journal
- Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
- (2021) Anja Strangfeld et al. ANNALS OF THE RHEUMATIC DISEASES
- Potential drug targets of SARS-CoV-2: From genomics to therapeutics
- (2021) Anas Shamsi et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2021) Obbina Abani et al. LANCET
- The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring
- (2021) Meenu Wadhwa et al. Frontiers in Immunology
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
- (2020) Milena Gianfrancesco et al. ANNALS OF THE RHEUMATIC DISEASES
- Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: Possible therapeutic implication in COVID-19
- (2020) Anas Shamsi et al. BIOSCIENCE REPORTS
- Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
- (2020) Evangelos J. Giamarellos-Bourboulis et al. Cell Host & Microbe
- The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system
- (2020) Francesca Coperchini et al. CYTOKINE & GROWTH FACTOR REVIEWS
- SARS‐CoV‐2, bacterial co‐infections, and AMR: the deadly trio in COVID‐19?
- (2020) Jose A. Bengoechea et al. EMBO Molecular Medicine
- Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
- (2020) Erica J. Brenner et al. GASTROENTEROLOGY
- COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal
- (2020) Hasan K. Siddiqi et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
- (2020) Marc Feldmann et al. LANCET
- Cell entry mechanisms of SARS-CoV-2
- (2020) Jian Shang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
- (2020) Bo Diao et al. Frontiers in Immunology
- Molecular immune pathogenesis and diagnosis of COVID-19
- (2020) Xiaowei Li et al. Journal of Pharmaceutical Analysis
- Heparin as a therapy for COVID-19: current evidence and future possibilities
- (2020) Joseph A. Hippensteel et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User’s Guide: An Update
- (2020) Marianne Vulliemoz et al. DIGESTION
- Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent
- (2020) Alessio Mazzoni et al. JOURNAL OF CLINICAL INVESTIGATION
- A single-cell atlas of the peripheral immune response in patients with severe COVID-19
- (2020) Aaron J. Wilk et al. NATURE MEDICINE
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive mapping of immune perturbations associated with severe COVID-19
- (2020) Leticia Kuri-Cervantes et al. Science Immunology
- Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study
- (2020) Satveer K. Mahil et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
- (2020) Qian Zhang et al. SCIENCE
- Autoantibodies against type I IFNs in patients with life-threatening COVID-19
- (2020) Paul Bastard et al. SCIENCE
- Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes
- (2020) Rajendra Karki et al. CELL
- Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis
- (2019) Anna Campanati et al. Expert Opinion on Drug Metabolism & Toxicology
- Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications
- (2018) Ulrich Kronthaler et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Anti-TNF Therapy in Crohn’s Disease
- (2018) Samuel O. Adegbola et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity
- (2018) Clive Metcalfe et al. mAbs
- Establishment of the first WHO International Standard for etanercept, a TNF receptor II Fc fusion protein: Report of an international collaborative study
- (2017) Meenu Wadhwa et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
- (2017) Changsoo Lee et al. mAbs
- Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment
- (2017) Joachim R. Kalden et al. Nature Reviews Rheumatology
- Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
- (2017) Rudragouda Channappanavar et al. Seminars in Immunopathology
- Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice
- (2016) Rudragouda Channappanavar et al. Cell Host & Microbe
- Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future
- (2016) Daniela Pugliese et al. Expert Review of Clinical Immunology
- Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
- (2016) Alon D. Levin et al. Journal of Crohns & Colitis
- Programmed Necrosis in the Cross Talk of Cell Death and Inflammation
- (2015) Francis Ka-Ming Chan et al. Annual Review of Immunology
- Necroptosis and its role in inflammation
- (2015) Manolis Pasparakis et al. NATURE
- The diverse role of RIP kinases in necroptosis and inflammation
- (2015) John Silke et al. NATURE IMMUNOLOGY
- TNF biology, pathogenic mechanisms and emerging therapeutic strategies
- (2015) George D. Kalliolias et al. Nature Reviews Rheumatology
- Anti-TNF therapy: past, present and future
- (2014) C. Monaco et al. INTERNATIONAL IMMUNOLOGY
- Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study
- (2014) Tsutomu Takeuchi et al. Modern Rheumatology
- Necroptosis
- (2014) Andreas Linkermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The mercurial nature of neutrophils: still an enigma in ARDS?
- (2013) Andrew E. Williams et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Role of Chemokines in the Pathogenesis of Acute Lung Injury
- (2012) Madhav Bhatia et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Anti-TNF therapy
- (2011) Nishanthi Thalayasingam et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases
- (2010) Peter C Taylor CURRENT OPINION IN PHARMACOLOGY
- A Tangled Web of Ubiquitin Chains: Breaking News in TNF-R1 Signaling
- (2009) Katiuscia Bianchi et al. MOLECULAR CELL
- Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab
- (2008) Hiroki Mitoma et al. ARTHRITIS AND RHEUMATISM
- TNF-α Induces Two Distinct Caspase-8 Activation Pathways
- (2008) Lai Wang et al. CELL
- Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor-α blockade
- (2008) Francesca Ingegnoli et al. JOURNAL OF AUTOIMMUNITY
- TNF-mediated inflammatory disease
- (2007) JR Bradley JOURNAL OF PATHOLOGY
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started